News Releases

August 9, 2022

Codex DNA Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Continued execution across all areas of the growth strategy:
Read more
June 2, 2022

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Friday, June 10 th at
Read more
May 10, 2022

Codex DNA Reports First Quarter 2022 Financial Results

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. “In the first quarter of 2022, we delivered robust revenue growth across our product
Read more
Displaying 1 - 10 of 19

About Codex DNA

Codex DNA, Inc. is building biology. Creators of the BioXp™ system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Codex DNA, Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA.

Codex DNA, Inc. is accelerating advances in the fields of personalized medicine, biologics drug discovery, vaccine development, genome editing, and cell and gene therapy.

Site

Links

All trademarks are the property of Codex DNA, Inc. or their respective owners. For specific trademark information, contact us at help@codexdna.com.
All content © 2022 Codex DNA, Inc. All rights reserved.

Codex DNA Logo